Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving the drug selection and development process for combination devices.

Maggie A Z Hupcey1, Sean Ekins

  • 1PA Consulting Group, 600 College Road East, Suite 1120, Princeton, NJ 08540, USA. maggie.hupcey@paconsulting.com

Drug Discovery Today
|October 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy, Structure-Activity Relationship, and Mode of Action Studies of a New Generation of Acridine/Acridone-Based Antimalarials.

ACS infectious diseases·2026
Same author

MegaTrans-machine learning models for drug transporters corresponding to the FDA guidance.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Repurposing Clinical Candidates for Nipah and Hendra Viruses.

ACS infectious diseases·2026
Same author

Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.

ACS omega·2026
Same author

Palmitoyl-protein thioesterase-1 in health and disease.

Trends in pharmacological sciences·2026
Same author

Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier.

Molecular genetics and metabolism·2026
Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
See all related articles

Developing combination devices requires careful drug selection by pharmaceutical and medical device companies. Addressing drug properties ensures optimal efficacy, surpassing the sum of individual components for successful product innovation.

Area of Science:

  • Pharmaceutical research
  • Medical device development
  • Drug delivery systems

Background:

  • Combination devices integrate pharmaceutical and medical device technologies.
  • Successful integration requires careful consideration of drug selection criteria.
  • Suboptimal drug property assessment can lead to product deficiencies.

Purpose of the Study:

  • To review the opportunities and challenges in combination device development.
  • To outline drug selection criteria for pharmaceutical and medical device companies.
  • To provide insights from both device and pharmaceutical perspectives.

Main Methods:

  • Literature review of combination device development.
  • Analysis of drug and biologic properties relevant to combination devices.

Related Experiment Videos

  • Examination of case studies and industry best practices.

    • Main Results:

    • Successful combination devices achieve synergistic efficacy.
    • Key challenges include detailed assessment of drug/biologic properties.
    • Development requires a multidisciplinary approach considering both components.

    Conclusions:

    • Strategic drug selection is crucial for combination device success.
    • Thorough evaluation of drug properties mitigates risks of suboptimal products.
    • Addressing development dimensions from both perspectives optimizes innovation.